The adult-onset form of Pompe disease had a wide clinical spectrum, ranging from asymptomatic patients with increased CK to muscle cramps and pain syndrome or rigid-spine syndrome. In addition clinical severity and disease progression are greatly variable. We report on a family with 3 siblings characterized by an unusual adult-onset Pompe disease including dysphagia and weakness of tongue, axial and limb-girdle muscles, in association with atypical globular inclusions in muscle fibres. Our study confirms the great clinical and histological variability of adult-onset Pompe disease and further supports the need of careful evaluation of bulbar function in patients affected by this pathology.

Key words: Pompe disease, globular inclusions; bulbar symptoms.

Glycogen storage disease type II (Pompe disease or acid maltase deficiency) is a rare autosomal recessive muscular disorder characterized by deficiency of acid-alfa glucosidase (GAA), determining accumulation of glycogen in the lysosomes, mainly in cardiac and skeletal muscle cells. Typical phenotypes of glycogenosis type II include the severe classic infantile form, characterized by severe muscle weakness and hypertrophic cardiomyopathy, almost invariably fatal by 12 months, a “non-classic” form presenting between 1 and 2 years of age and the late-onset form, presenting at any time after the age of 1 year, including juvenile and adult-onset subtypes, which are considered as part of a continuous clinical spectrum (1). In particular the adult-onset form presents with slowly progressive proximal lower limb and/or paraspinal muscle weakness, often followed by restrictive respiratory failure, which could be life-threatening, as it is in infants and children (2). However the clinical spectrum of adult-onset form is wide, ranging from asymptomatic patients with increased CK to muscle cramps and pain syndrome or rigid-spine syndrome (2, 3). Furthermore clinical severity and disease progression is greatly variable.

We report on a family with 3 siblings with an unusual adult-onset Pompe disease clinically characterized by weakness of bulbar, axial and limb-girdle muscles in association with atypical histopathological changes.

Case report

Clinical features

Patients were siblings born from non-consanguineous parents.

Patient 1 is a 47 year-old male, who came to our attention because of difficulty in moving tongue and lips and swallowing, occurring since the age of 43. Furthermore he noticed mild limb muscle wasting and weakness during the disease course. Neurological examination at the age of 45 years showed tongue hypotrophy and weakness without fasciculations (Fig. 1), moderate orbicularis oculi and oris weakness, waddling gait with knee hyperextension and marked spine lordosis, mild neck flexor, moderate proximal upper and lower limb muscle weakness and mild thoracic scoliosis. Electromyography showed neurogenic changes in all examined limb muscles, myopathic at genioglossum and neuromyogenic at orbicularis oculi and oris. Sensory and motor nerve conduction studies were normal.
Patient 2 is a 56-year-old woman, having CK mildly increased (range 564-634 U/L; normal value 24-195) since the age of 38, when it was assessed for the first time, and not further investigated. At the age of 48 she noticed lower limb weakness and at the age of 53 respiratory problems and mild dysphagia. On examination at first admission in our institute at the age of 54 years she displayed marked head flexors and thigh extensor muscle weakness with waddling gate, tongue hypotrophy and weakness (Fig. 1).

Patient 3 is a 53-year-old woman, complaining of dysphagia since the age of 41 and experiencing walking difficulty since the age of 46, followed by mild upper limbs weakness and respiratory difficulties. However she has never been able to run properly. Neurological examination at the age of 51 years revealed marked waddling gait and increased lumbar lordosis, moderate to marked head flexors, lower and upper limb girdle muscle weakness. Tongue was hypotrophic and weak.

Histological features

Muscle biopsies were performed after informed consent, on the quadriceps muscle in all three patients. In patient 1 the biopsy, taken at age 45, showed a few vacuolated fibres containing Periodic-Acid-Shiff (PAS) and acid phosphatase positive material that, on haematoxylin-eosin (H&E) preparations, appeared constituted of round or oval bluish globules (Fig. 3). Oxidative enzymes and ATPase staining were normal. Globular inclusions appeared blue with menadione-linked alpha-glycerophosphate dehydrogenase (menadione-nitroblue tetrazolium). Similar findings, although vacuoles were more numerous but smaller, were observed in patient 2 (Fig. 3). In patient 3, PAS and acid phosphatase-positive material was more abundant and almost totally substituted the cytoplasm of several fibres (Fig. 3). Muscle biopsies in patient 2 and 3 were performed at the age of 57 and 51, respectively.

Immunostaining of EEA1, LC3, LAMP2 showed that the inclusions were mainly positive for LAMP2 (marker of lysosomes), and variably positive for EEA1 and LC3 (markers of early and late autophagy, respectively); several autofluorescent lipofuscin bodies were also present. Desmin, dystrophin, dystrophin-associated proteins, laminin-α2, caveolin 3 were normally expressed in all 3 patients.

Electron microscopy of muscle tissue showed diffuse intramyofibrillar increase of glycogen particles and, in some fibres, small membrane-limited round bodies containing densely packed glycogen particles (Fig. 4). Large areas occupied by autophagic, lysosomal and lipofuscin material intersperse with glycogen particles were also observed in a few fibres. Small globular bodies were more frequent in patient 2.

Biochemical analysis on muscle tissue of patient 1 and 2 revealed severely reduced GAA activity (both with 0.6 nmol/h/mg of protein, normal value 2.7-15). Patient 3 had 1.0 nmol/h/mg residual acid maltase activity on muscle tissue.

Genetic features

Molecular analysis through gene direct sequencing in all patients revealed two mutations in GAA gene, c.-32-13T>G in intron 1 leading to aberrant splicing of exon 2,
associated with the juvenile/adult onset (5, 6) and the intron 10 mutation c.1551+1G>C (p.Val480-Ile517del) associated in some patients with a more severe disease (7), consistent with a diagnosis of Pompe disease. Both mutations have been reported (5-9). A brother and the mother, both carrying the c.1551+1G>C mutation in heterozygosis, were asymptomatic. The other 2 brothers were negative for both mutations and healthy. Father died several years ago, hence molecular analysis was not available.

Clinical course and treatment

Once obtained the diagnosis of Pompe disease, the enzyme-replacement therapy (ERT) at standard dose (20 mg/kg every two weeks) was started in our patients at an age ranging from 45 to 54 years, while nocturnal non invasive ventilation (NIV) was started at an age ranging from 46 to 54 years, due to reduced nocturnal oxygen saturation. All patients had a reduction of forced vital capacity (FVC) which was further reduced in the lying position, from 17 to 29% of predicted values.

At last follow-up visit, after ERT, patient 1 and 2 had a further FVC reduction in the lying position of 34% and 22%, respectively, whereas in patient 3 this value was not available. Heart clinical evaluation and ECG were normal in all affected patients. Patients’clinical data, including assessment at baseline and at the end of the follow up period, are showed in Table 1.

The videofluoroscopic swallowing examination performed in patient 1 and 2, showed a mild impairment due to delayed tongue motion and slow oral transit, a moderate post-swallow pharyngeal residue and no penetration or aspiration. A facial CT scan performed in patient 1 at the age of 46 and a facial MRI scan performed in patient 2 at the age of 54, showed fat replacement of the tongue muscles.

Muscle MRI - performed at the age of 46 in patient 1 and 54 in patient 2 - obtained T1-weighted axial images at thigh and leg level according to standard protocol (4). As shown in figure 2, patient 1 had fatty degenerative changes of adductor magnus, longus and minimal of left biceps femoris, whereas patient 2 displayed a more diffuse involvement of posterior thigh muscles. No relevant findings were observed in leg muscles.

Bulbar symptoms did not change during follow-up period. On the contrary all patients had clinical benefit from starting ERT and/or NIV, as revealed by a better performance at 6MWT that improved from 18 to 100 metres.

Discussion

Clinical presentation of late-onset Pompe disease is largely variable, ranging from asymptomatic patients to severe proximal and diaphragmatic myopathy, with need

Figure 3. Histological stainings of muscle biopsies from patient 1 (A, B), 2 (C, D) and 3 (E, F). H&E (A,E) and Gomori Trichrome show grossly vacuolated fibres in patients 1 and 3 (more numerous in the latter) and finely vacuolated fibres in patient 2. Vacuoles contain PAS (B,F) and acid phosphatase-positive material. Bar = 50 μm

Figure 4. Electron micrographs muscle showing large non membrane-bound vacuoles containing autophagic material (A) and free glycogen particles (B) and lysosomes filled with glycogen particles (C, D) in the muscle of patient 1 (A, B) and 2 (C, D). Bar = 1 μm
reported as first symptoms and in particular patient 1 was first investigated elsewhere for disease of central nervous system. Patient 2 – presenting increased CK values – was asymptomatic for many years and presented bulbar symptoms only 5 years after the onset of lower limb weakness, confirming the great phenotypic variability of the disease. Patient 1 complained also difficulty in moving lips; facial muscle involvement was confirmed by neurological examination and electromyography. Tongue involvement with macroglossia – traditionally described in infants with classic phenotype – was considered a rare finding in late-onset disease. However tongue weakness has been reported in 19 patients affected by late-onset Pompe disease (17), one third of them complaining for swallowing difficulties, such as impairment of oral bolus control, and not further investigated. In that series tongue weakness was mild and only detected on neurological examination, being usually underestimated by the patients. On the contrary in our patients tongue weakness was more marked according to criteria established by Dubrovski and colleagues and reported as first symptom by patient 1. Fur-

| Patient | Patient 2 | Patient 3 |
|---------|-----------|-----------|
| Age at onset (years) of symptoms | 43 | 48 | 41 |
| Main symptoms at onset | bulbar | CK | bulbar |
| Predominant muscle weakness | proximal | axial/proximal | axial/proximal |
| Dysphagia | + | + | + |
| Age at first assessment | 45 | 54 | 51 |
| Tongue weakness/hypotrophy | +/+ | +/+ | +/+ |
| WGMS grade | 2 | 3 | 3 |
| FVC while sitting (%) | 76 | 54 | 42 |
| FVC while lying (%) | 47 | 37 | 22 |
| Nocturnal sO2 <90% time (%) | 20 | 34 | 49.2 |
| BMI | 19.8 | 25.8 | 27 |
| Muscle GAA activity (nmol/h/mg) | 0.6 | 0.6 | 1.0 |
| Age at ERT beginning (years) | 45 | 54 | 51 |
| Age at NIV beginning (years) | 46 | 54 | 52 |
| Age at last F-up (years) | 47 | 56 | 52 |
| WGMS grade | 2 | 3 | 3 |
| 6MWT range last-1st F-up (metres) | +100 | +32 | +18 |
| FVC while sitting (%) | 76 | 47 | 49 |
| FVC while lying (%) | 42 | 25 | na |
| Nocturnal sO2 <90% time (%) | 0.8 | 23 | na |
| BMI | 20.9 | 25.8 | 26.6 |

**Legenda.** FVC: forced vital capacity (% of predicted normal values); F-up: follow-up; WGMS: Walton and Gardner-Medwin scale; 6MWT: 6 minute walking test; sO2: oxygen saturation; BMI: body mass index; ERT: enzyme replacement therapy; NIV: non invasive ventilation; na: not available.
Familial adult-onset Pompe disease associated with unusual clinical and histological features

thermore tongue weakness had a main role in swallowing difficulties as showed by videofluoroscopy swallowing examination performed in our patients. Differently from data reported by Dubrovski and colleagues, all our patients displayed also tongue hypotrophy. As a matter of fact tongue involvement detected in our patients was also supported by facial CT and MRI findings in patients 1 and 2, respectively, that showed fatty degeneration, according to previously reported studies (16, 17). Recently Hobson-Webb and colleagues reported that 3/12 patients affected by late-onset Pompe disease showed oropharyngeal dysphagia, although none of them as first symptom (18). These 3 patients had tongue weakness and, to be noticed, dysphagia was confirmed through videofluoroscopic swallowing examination. In this respect patient 1 and 2 of our series underwent a videofluoroscopic swallowing examination, which resulted mildly impaired exclusively due to tongue weakness. Dysphagia remained stable over the years in our patients; this is also confirmed by BMI, which did not substantially change during the follow-up period.

Our data confirm that tongue weakness and dysphagia may occur in adult-onset Pompe disease more frequently than expected and need adequate investigations for early detection and management, being the most relevant symptoms in some cases. Bulbar involvement in patients affected by Pompe disease seems to be not associated with specific mutations, hence no genotype–phenotype correlation can be found.

Globular inclusions detected in our patients represent a rare finding. Their appearance with menadione-linked alpha-glycerophosphate dehydrogenase was in accordance with reducing bodies definition. However both the location in autophagic vacuoles and their electron density were not typical of classical reducing bodies, as observed also by Sharma and colleagues. Positivity to LAMP2 immunostaining suggests that globular inclusions should be considered mainly of lysosomal nature. However autophagic process could be concomitant, as several inclusions were also mildly positive to the markers of autophagy EEA1 and LC3.

Globular inclusions in glycogenosis type II have already been described in 6 unrelated patients (21-23), 3 in infancy and 3 in adult life. Two of them, including one adult-onset case, carried the c.IVS1-13T>G mutation, the same detected in our patients; in one infantile case molecular characterization was not available (21). The 3 patients with onset in infancy presented with delay in motor development, followed by mild to moderate muscle weakness, while patients with adult onset had mild-to-moderate proximal lower limb weakness, except one patient who was wheelchair bound and required NIV at the end of follow-up period (21-23). However no bulbar symptom was reported in these patients. In conclusion our study confirms the great clinical and histological variability of adult-onset Pompe disease and further supports the need of a careful evaluation of bulbar function in patients affected by this pathology.

Acknowledgements

The study was supported by the Italian Ministry of Health. CB was supported by a grant of the Italian Glycogenosis Association.

References

1. Bembi B, Cerini E, Danesino C, et al. Diagnosis of glycogenosis type II. Neurology 2008;71:S4-11.
2. Van der Ploeg AT, Reuser AJ. Pompe’s disease. Lancet 2008;372:1342-53.
3. Laforêt P, Doppler V, Caillaud C, et al. Rigid spine syndrome revealing late-onset Pompe disease. Neuromuscul Disord 2010;20:128-30.
4. Mercuri E, Pichiecchio A, Counsell S, et al. A short protocol for muscle MRI in children with muscular dystrophies. Eur J Paediatr Neurol 2002;6:305-7.
5. Huie ML, Chen AS, Tsujino S, et al. Aberrant splicing in adult onset glycogen storage disease type II: molecular identification of an IVS1 (-13 T→G) mutation in a majority of patients and a novel IVS10 (+1GT→CT) mutation. Hum Mol Genet 1994;3:2231-6.
6. Kroos MA, Van der Kraan M, Van Diggelen OP, et al. Glycogen storage disease type II: frequency of three common mutant alleles and their associated clinical phenotypes studied in 121 patients. J Med Genet 1995;32:836-7.
7. Stroppiano M, Bonuccelli G, Corsolini F, et al. Aberrant splicing at catalytic site as cause of infantile onset glycogen storage disease type II (GSDII): molecular identification of a novel IVS9 (+2GT→-gt;GC) in combination with rare IVS10 (+1GT→-gt;CT). Am J Med Genet 2001;101:55-8.
8. Boerkoel CF, Exelbert R, Nicastri C, et al. Leaky splicing mutation in the acid maltase gene is associated with delayed onset of glycogenosis type II. Am J Hum Genet 1995;56:887-97.
9. Alcántara-Ortigoza MA, González-del Angel A, Barrientos-Ríos R, et al. Screening of late-onset Pompe disease in a sample of Mexican patients with myopathies of unknown etiology: identification of a novel mutation in the acid alpha-glucosidase gene. J Child Neurol 2010;25:1034-7.
10. Angelini C, Semplicini C, Ravaglia S, et al. Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4 years. J Neurol 2012;259:952-8.
11. Güngör D, Kruijshaar ME, Plug I, et al. Impact of enzyme replacement therapy on survival in adults with Pompe disease: results from a prospective international observational study. Orphanet J Rare Dis 2013;8:49.
12. Jones HN, Muller CW, Lin M, et al. Oropharyngeal dysphagia in infants and children with infantile Pompe disease. Dysphagia 2010;25:277-83.
13. Van Gelder CM, van Capelle CI, Ebbink BJ, et al. Facial-muscle weakness, speech disorders and dysphagia are common in patients with classic infantile Pompe disease treated with enzyme therapy. J Inherit Metab Dis 2012;35:505-11.
14. Barnes D, Hughes RA, Spencer GT. Adult-onset acid maltase deficiency with prominent bulbar involvement and ptosis. J R Soc Med 1993;86:50.
15. Felice KJ, Alessi AG, Grunnet ML. Clinical variability in adult-onset acid maltase deficiency: report on affected sibs and review of the literature. Medicine (Baltimore) 1995;74:131-5.
16. Carlier RY, Laforet P, Wary C, et al. Whole-body muscle MRI in 20 patients suffering from late onset Pompe disease: Involvement patterns. Neuromuscul Disord 2011;21:791-9.
17. Dubrowski A, Corderi J, Lin M, Kishnani PS, Jones HN. Expanding the phenotype of late-onset Pompe disease: tongue weakness: a new clinical observation. Muscle Nerve 2011;44:897-901.
18. Hobson-Webb LD, Jones HN, Kishnani PS. Oropharyngeal dysphagia may occur in late-onset Pompe disease, implicating bulbar muscle involvement. Neuromuscul Disord 2013;23:319-23.
19. Van der Walt JD, Swash M, Leake J, Cox EL. The pattern of involvement of adult-onset maltase deficiency at autopsy. Muscle Nerve 1987;10:272-81.
20. Van der Beek NA, de Vries JM, Hagemans MLC, et al. Clinical features and predictors for disease natural progression in adults with Pompe disease: a nationwide prospective observational study. Orphanet J Rare Dis 2012;7:88.
21. Jay V, Christodoulou J, Mercer-Connolly A, McInnes RR. “Reducing body”-like inclusions in skeletal muscle in childhood-onset acid maltase deficiency. Acta Neuropathol 1992;85:111-5.
22. Sharma MC, Schultz C, von Moers A, et al. Delayed or late-onset type II glycogenosis with globular inclusions. Acta Neuropathol 2005;110:151-7.
23. Tsabaraya RS, Monma K, Oya Y, et al. Acid phosphatase-positive globular inclusions is a good diagnostic marker for two patients with adult-onset Pompe disease lacking disease specific pathology. Neuromuscul Disord 2012;22:389-93.